Lonza Group AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LZAGF research report →
About the company
Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors. Its operational footprint extends across Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and beyond. The company's activities are organized into four primary divisions: Biologics: This segment is dedicated to the contract development and manufacturing (CDMO) of biopharmaceuticals, offering extensive support for both drug substances and finished drug products throughout their entire lifecycle, from clinical trials to commercial-scale production.
- CEO
- Wolfgang Wienand
- IPO
- 2009
- Employees
- 17,995
- HQ
- Basel, CH
Price Chart
- Market Cap
- $49.42B
- P/E
- -146.48
- P/S
- 6.14
- P/B
- 4.41
- EV/EBITDA
- 24.20
- Div Yield
- 0.87%
- Gross Margin
- 34.63%
- Op Margin
- 21.01%
- Net Margin
- -4.21%
- ROE
- -3.10%
- ROIC
- 7.22%
- Revenue
- $6.53B · -0.65%
- Net Income
- $949.00M · 49.21%
- EPS
- $13.55 · 51.74%
- Op Income
- $1.24B
- FCF YoY
- -51.75%
- 52W High
- $755.96
- 52W Low
- $565.14
- 50D MA
- $633.00
- 200D MA
- $664.24
- Beta
- 0.85
- Avg Volume
- 380
Get TickerSpark's AI analysis on LZAGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LZAGF coverage
Recent articles, reports, and earnings notes.
No research on LZAGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LZAGF report →Similar companies
Peers in the same neighborhood.